OncoTargets and Therapy (Aug 2020)
Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
Abstract
Weiwei Huang,1 Chao Li,2 Mulan Chen,1 Duanyu Lin,3 Fan Wu,1 Xinhua Chen,1 Nani Li,1 Lili Wang,1 Jian Liu1 1Department of Medical Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, The Teaching Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, People’s Republic of China; 2Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, The Teaching Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, People’s Republic of China; 3Department of Imaging, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, The Teaching Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, People’s Republic of ChinaCorrespondence: Jian Liu Tel +86-13906912727Email [email protected]: A 62-year-old postmenopausal woman was diagnosed with breast cancer in her left breast and received modified radical mastectomy (molecular type: hormone-receptor-positive human epidermal growth factor receptor-2 negative). After that, she received postoperative chemotherapy and radiotherapy. After 2 years of tamoxifen adjuvant endocrine treatment, the patient inccurred recurrence with metastasis. PET-CT scanning showed metastasis in the left thoracic wall, the sixth left rib, and the right lower lobe of the lung. Multiple lymph node metastases were observed throughout the body. Palbociclib in combination with an aromatase inhibitor (AI) was used, but the metastatic lesion at the sixth left rib increased than before. Subsequently, the lesion shrunk and the clinical symptoms were relieved, which was considered as a pseudoprogression. Herein, we reported a pseudoprogression in the breast cancer patient after treatment with palbociclib plus AI.Keywords: pseudoprogression, palbociclib, breast cancer
